JPS6113715B2 - - Google Patents

Info

Publication number
JPS6113715B2
JPS6113715B2 JP53056126A JP5612678A JPS6113715B2 JP S6113715 B2 JPS6113715 B2 JP S6113715B2 JP 53056126 A JP53056126 A JP 53056126A JP 5612678 A JP5612678 A JP 5612678A JP S6113715 B2 JPS6113715 B2 JP S6113715B2
Authority
JP
Japan
Prior art keywords
butyl
phenol
bis
compounds
thenoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP53056126A
Other languages
Japanese (ja)
Other versions
JPS53141265A (en
Inventor
Gaua Inisu Muua Jooji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Riker Laboratories Inc
Original Assignee
Riker Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riker Laboratories Inc filed Critical Riker Laboratories Inc
Publication of JPS53141265A publication Critical patent/JPS53141265A/en
Publication of JPS6113715B2 publication Critical patent/JPS6113715B2/ja
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28Halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は、3・5−ビス(t−ブチル)−4−
ヒドロキシフエニル−置換チオフエンおよび3・
5−ビス(t−ブチル)−4−ヒドロキシベンゾ
イル−置換チオフエン、このような化合物の抗炎
症剤としての使用、このような化合物の1種若し
くは2種以上と適当な製薬上の増量媒体との組合
せからなる抗炎症剤組成物および本発明の最終生
成化合物の調製に有用な新規中間体に関する。 ビス(t−ブチル)フエノール基が置換してい
るチオフエン化合物はこれまで知られていなかつ
た。本発明者が知り得るかぎりにおいては、モノ
−t−ブチルフエノール基が置換しているチオフ
エンでさえも知られていない。しかしながら、4
−(2′−チエニル)フエノール、4−(3′−チエニ
ル)フエノール、3−(2′−チエニル)フエノー
ル、3−(3′−チエニル)フエノールおよび2−
(2′−テノイル)フエノールのような化合物は知
られている。 本発明は特に次式の化合物に関する: 〔式中、Lはカルボニルあるいは炭素−炭素結合
であり、そしてRは水素、メチルあるいはハロゲ
ン(弗素、塩素、沃素あるいは臭素)である〕。
Lがカルボニル、特にLが2−カルボニルである
式の化合物はそれらの合成の容易性と高い治療
係数の点からして現在のところ好ましい。また、
Rが水素またはハロゲン、特にRが水素または塩
素である本発明の化合物が好ましい。Rが水素で
はない本発明の化合物においては、LとRとがチ
オフエン環の隣接する炭素原子に結合しておら
ず、そしてRが沃素でないことが好ましい。 本発明の化合物は有効な抗炎症剤として使用さ
れる以外にも、酸化を防止するための安定剤とし
ても比較的活性である。また幾つかの化合物は鎮
痛剤であり、幾つかの化合物は解熱剤であり、そ
して幾つかの化合物は温和な免疫抑制活性を有し
ている。 薬理学上の活性を測定し且つ評価する目的で、
当業者に公知の各種の試験を用いて動物テストを
行つた。本発明の化合物の抗炎症活性は、炎症応
答に特徴的である局部浮腫を治ゆするこの化合物
の能力をテストするように設計した試験方法(ラ
ツトの足の浮腫テスト)を用いて都合よく実証す
ることができる。上記の化合物()が、酵素プ
ロスタグランジン・シンゼターゼ(synthelase)
を抑制することも見い出した。このプロスタグラ
ンジン・シンゼターゼ抑制試験は抗炎症活性の検
出用の広い選別法であり、このことはH.L.ホワ
イトおよびA.T.グロスマンにより、プロスタグ
ランジンズ(Prostaglandins)7(2):123〜129
(1974)の「ア・シンプル・ラジオケミカル・ア
セイ・フオア・プロスタグランデイン・シンゼタ
ーゼ(A Simple Radiochemical Assay for
Prostaglandin Synthetase)」中に記載されてい
る。 本発明の化合物は皮膚に投薬するときに非常に
活性である。このような局所活性はモルモツト紅
斑テストを用い、そして接触感応テストにより測
定した。抗炎症活性も、木綿ペレツト肉芽腫テス
トや補薬関節炎テストのように当業者に公知の他
の試験方法により検出し得る。その鎮痛活性もフ
エニルキノン苦痛(マウス)やランダルーセリツ
ト(Randall−Selitto)(ラツト)テストのような
標準テストにおいて観察された。 ラツトの足の浮腫方法に関する文献としては次
のものがある: (1) アダムキエヴイツク(Adamk iewicz)等、
Canad、J.Biochem.Physio.33:332、1955: (2) セライ(Selye)、Brit.Med.J.2:1129、
1949:および (3) ウインター(Winter)、Proc.Exper.Biol.
Med.111:544、1962。 本発明の化合物は、抗炎症剤として好ましくは
経口的に投薬されるが、他の公知の投薬方法、例
えば粘膜皮膚投薬(例えば皮膚投薬、直腸投薬
等)並びに、例えば皮下注射、筋肉内注射、関節
内注射、静脈内注射等による非経口投薬も同様に
意図される。目の投薬も含まれる。投薬量は、治
療される哺乳動物の体重1Kg当り約1〜500mgの
範囲内が普通であるが、経口投与量は通常は100
mg/Kgを越えない。 抗炎症活性に関して、現在のところ好ましい本
発明の化合物としては、2・6−ビス(t−ブチ
ル)−4−(2′−テノイル)フエノール、2・6−
ビス(t−ブチル)−4−(2′−チエニル)フエノ
ール、2・6−ビス(t−ブチル)−4−(3′−テ
ノイル)フエノールおよび2・6−ビス(t−ブ
チル)−4−(5′−クロロ−2′−テノイル)フエノ
ールを包含する。現在のところ、皮膚活性に関し
て好ましい本発明の化合物は2・6−ビス(t−
ブチル)−4−(2′−テノイル)フエノールおよび
2・6−ビス(t−ブチル)−4−(5′−クロロ−
2′−テノイル)フエノールである。 Lが炭素−炭素結合である本発明の化合物は、
2・6−ビス(t−ブチル)ベンゾキノンを、適
当なハロゲン化チオフエンから調製したグリニヤ
ール試薬と反応させることにより容易に調製され
る。ハロゲン化チオフエン並びにその調製方法は
当該技術分野で周知である。公知のハロゲン化チ
オフエンは2−ヨードチオフエン、2−ブロモチ
オフエン、2−クロロチオフエン、2−フルオロ
チオフエン等がある。 ハロゲン化チオフエンのグリニヤール試薬と
2・6−ビス(t−ブチル)ベンゾキノンとの間
のグリニヤール反応により、中間体である次式
の、置換基を有してもよい2・6−ビス(t−ブ
チル)−4−ヒドロキシ−4−(チエニル)−2・
5−シクロヘキサジエン−1−オンが得られる。 (式中、Rは前記と同意義、すなわち水素、メチ
ルあるいはハロゲンである)。これらの化合物
()は新規であり、そして本発明の範囲内にあ
る。これらの化合物は、水素ガスと、木炭上のパ
ラジウムあるいはラネーニツケルのような触媒と
の組合せ、リチウムアルミニウムハイドライドの
ような金属ハイドライド還元剤あるいは沃化水素
を用いて還元されて、式()の本発明の化合物
を形成する。上述の反応においてグリニヤール試
験を用いる代りに、リチウム化合物のような公知
の反応性均等物も有用である。 Lがカルボニル基である本発明の化合物は幾つ
かの方法で容易に調製される。フリーデルークラ
フト触媒の存在下における3・5−ビス(t−ブ
チル)−4−ヒドロキシベンゾイルクロライドと
置換基を有してもよいチオフエンとの反応は、L
がチオフエンの2−位置に結合したカルボニルで
あり、Rが3−または5−位置にある化合物の合
成に有用である。有用なフリーデルークラフト触
媒としては、塩化アルミニウム、四塩化チタン、
塩化亜鉛などがある。この反応は一般に、所望に
より窒素のような不活性ガス雰囲気下で上記のベ
ンゾイルクロライドを二硫化炭素、ジクロロエタ
ン、ジクロロメタンのような不活性溶剤中に溶解
し、室温でフリーデルークラフト触媒を加え、そ
して次にチオフエン成分を滴下して加え、そして
反応を完結するまで進行させることにより行われ
る(反応の完結は塩化水素の発生の終了によつて
判る)。反応を促進するために時には加熱や加温
が有益である。 一方、2・6−ビス(t−ブチル)フエノール
はフリーデルークラフト反応で適当なチオフエン
カルボニルクロライドと反応させることができ
る。その方法は標準のフリーデルークラフト技術
を用いて本質的に上述の如くである。塩化アルミ
ニウムでは反応速度が速すぎるならば、四塩化チ
タンのような一層弱い触媒を使用するのが好まし
い。別の代替できる方法としては、フリーデルー
クラフト触媒により、1またはそれ以上の第三級
ブチル基を4′−チエニルフエノール核あるいは
4′−テノイルフエノール核に直接導入する方法が
ある。 上述の方法を用いる本発明の化合物の調製方法
を次の実施例を用いて説明する。 実施例 1 二硫化炭素300ml中の3・5−ビス(t−ブチ
ル)−4−ヒドロキシベンゾイルクロライド26.9
g(0.10モル)の溶液に、13.5gの塩化アルミニ
ウムを加えた。15分間撹拌し且つわずかに温めた
後に2−ブロモチオフエン17g(0.104モル)を
加えた。この反応混合物は徐々に緑色からくり色
に変つた。次にこれを10%塩酸中に注入し、そし
てジクロロメタンで抽出した。この抽出液を乾燥
し、次に溶媒を蒸発させて、容易に結晶化する油
を得た。脱色用木炭で処理しながらヘキサンから
再結晶化させて2・6−ビス(t−ブチル)−4
−(5′−ブロモ−2′−テノイル)フエノール(m.
p.126〜127.5℃)を得た。 分析: C19H23BrO2Sとしての %C %H 計算値:57.7:5.9 実測値:57.6:5.9 実施例1の方法を実質的に利用し(そしてチオ
フエン出発物質を適当な物質に取換えて)次の化
合物を得た:
The present invention provides 3,5-bis(t-butyl)-4-
Hydroxyphenyl-substituted thiophene and 3.
5-bis(t-butyl)-4-hydroxybenzoyl-substituted thiophenes, the use of such compounds as anti-inflammatory agents, the combination of one or more such compounds with suitable pharmaceutical bulking vehicles; The present invention relates to novel intermediates useful in the preparation of combination anti-inflammatory compositions and final product compounds of the present invention. A thiophene compound substituted with a bis(t-butyl)phenol group has not been known so far. To the best of the inventor's knowledge, even thiophenes substituted with mono-t-butylphenol groups are unknown. However, 4
-(2'-thienyl)phenol, 4-(3'-thienyl)phenol, 3-(2'-thienyl)phenol, 3-(3'-thienyl)phenol and 2-
Compounds such as (2'-thenoyl)phenol are known. The invention particularly relates to compounds of the formula: [wherein L is carbonyl or a carbon-carbon bond, and R is hydrogen, methyl or halogen (fluorine, chlorine, iodine or bromine)].
Compounds of the formula in which L is carbonyl, especially L is 2-carbonyl, are presently preferred because of their ease of synthesis and high therapeutic index. Also,
Preference is given to compounds according to the invention in which R is hydrogen or halogen, especially R is hydrogen or chlorine. In compounds of the invention where R is hydrogen, it is preferred that L and R are not bonded to adjacent carbon atoms of the thiophene ring and that R is not iodine. In addition to being used as effective anti-inflammatory agents, the compounds of the present invention are also relatively active as stabilizers to prevent oxidation. Also, some compounds are analgesics, some are antipyretics, and some have mild immunosuppressive activity. For the purpose of measuring and evaluating pharmacological activity,
Animal testing was performed using various tests known to those skilled in the art. The anti-inflammatory activity of the compounds of the invention is conveniently demonstrated using a test method (rat paw edema test) designed to test the ability of this compound to ameliorate the local edema that is characteristic of inflammatory responses. can do. The above compound () is the enzyme prostaglandin synthetase (synthelase).
It was also found that it suppresses This prostaglandin synthetase inhibition test is a broad screening method for the detection of anti-inflammatory activity, which was described by HL White and AT Grossman in Prostaglandins 7(2):123-129.
(1974) “A Simple Radiochemical Assay for Prostaglandin Synthetase”
Prostaglandin Synthetase). The compounds of this invention are highly active when administered to the skin. Such local activity was determined using the guinea pig erythema test and by the contact sensitivity test. Anti-inflammatory activity may also be detected by other test methods known to those skilled in the art, such as the cotton pellet granuloma test or the adjuvant arthritis test. Its analgesic activity was also observed in standard tests such as the phenylquinone pain (mice) and Randall-Selitto (rats) tests. Literature on rat paw edema methods includes: (1) Adamk iewicz et al.
Canad, J.Biochem.Physio.33:332, 1955: (2) Selye, Brit.Med.J.2:1129,
1949: and (3) Winter, Proc.Exper.Biol.
Med.111:544, 1962. The compounds of the invention are preferably administered orally as anti-inflammatory agents, although other known methods of dosing may be used, such as mucocutaneous administration (e.g. dermal administration, rectal administration, etc.) as well as e.g. subcutaneous injection, intramuscular injection, etc. Parenteral administration by intra-articular injection, intravenous injection, etc. is also contemplated. This includes eye medications. Dosages are usually in the range of about 1 to 500 mg/kg of body weight of the mammal being treated, although oral doses are usually about 100 mg/kg body weight of the mammal being treated.
Do not exceed mg/Kg. Presently preferred compounds of the invention with respect to anti-inflammatory activity include 2,6-bis(t-butyl)-4-(2'-thenoyl)phenol, 2,6-
Bis(t-butyl)-4-(2'-thienyl)phenol, 2,6-bis(t-butyl)-4-(3'-thenoyl)phenol and 2,6-bis(t-butyl)-4 -(5'-chloro-2'-thenoyl)phenol. Presently preferred compounds of the invention with respect to skin activity are 2,6-bis(t-
butyl)-4-(2'-thenoyl)phenol and 2,6-bis(t-butyl)-4-(5'-chloro-
2′-Thenoyl)phenol. Compounds of the present invention in which L is a carbon-carbon bond,
It is easily prepared by reacting 2,6-bis(t-butyl)benzoquinone with a Grignard reagent prepared from the appropriate halogenated thiophene. Halogenated thiophenes and methods of their preparation are well known in the art. Known halogenated thiophenes include 2-iodothiophene, 2-bromothiophene, 2-chlorothiophene, and 2-fluorothiophene. By the Grignard reaction between the Grignard reagent of halogenated thiophene and 2,6-bis(t-butyl)benzoquinone, the intermediate 2,6-bis(t- butyl)-4-hydroxy-4-(thienyl)-2.
5-cyclohexadien-1-one is obtained. (wherein R has the same meaning as above, ie hydrogen, methyl or halogen). These compounds () are new and within the scope of the present invention. These compounds are reduced using a combination of hydrogen gas and a catalyst such as palladium on charcoal or Raney nickel, a metal hydride reducing agent such as lithium aluminum hydride, or hydrogen iodide to form the present invention of formula (). Forms a compound of Instead of using the Grignard test in the reactions described above, known reactive equivalents such as lithium compounds are also useful. Compounds of the invention in which L is a carbonyl group are readily prepared in several ways. The reaction of 3,5-bis(t-butyl)-4-hydroxybenzoyl chloride with optionally substituted thiophene in the presence of a Friedel-Crafts catalyst is
is a carbonyl attached to the 2-position of the thiophene, and R is useful in the synthesis of compounds in the 3- or 5-position. Useful Friederu-Crafts catalysts include aluminum chloride, titanium tetrachloride,
These include zinc chloride. This reaction generally involves dissolving the benzoyl chloride described above in an inert solvent such as carbon disulfide, dichloroethane, dichloromethane, optionally under an inert gas atmosphere such as nitrogen, adding a Friederu-Crafts catalyst at room temperature, and The thiophene component is then added dropwise and the reaction is allowed to proceed to completion, as indicated by the end of hydrogen chloride evolution. Heating or warming is sometimes beneficial to accelerate the reaction. On the other hand, 2,6-bis(t-butyl)phenol can be reacted with a suitable thiophene carbonyl chloride in a Friedel-Crafts reaction. The method is essentially as described above using standard Friederu-Craft techniques. If the reaction rate is too fast for aluminum chloride, it is preferred to use a weaker catalyst such as titanium tetrachloride. Another alternative is to convert one or more tertiary butyl groups to a 4'-thienylphenol nucleus or
There is a method of directly introducing it into the 4'-tenoylphenol nucleus. The following examples illustrate how to prepare compounds of the invention using the methods described above. Example 1 3,5-bis(t-butyl)-4-hydroxybenzoyl chloride in 300 ml of carbon disulfide 26.9
g (0.10 mol) of solution, 13.5 g of aluminum chloride was added. After stirring for 15 minutes and warming slightly, 17 g (0.104 mol) of 2-bromothiophene was added. The reaction mixture gradually turned from green to amber. This was then poured into 10% hydrochloric acid and extracted with dichloromethane. The extract was dried and then the solvent was evaporated to give an oil that crystallized easily. 2,6-bis(t-butyl)-4 was recrystallized from hexane while being treated with decolorizing charcoal.
-(5′-bromo-2′-thenoyl)phenol (m.
p.126-127.5℃) was obtained. Analysis: %C as C 19 H 23 BrO 2 S %H Calculated: 57.7:5.9 Found: 57.6:5.9 Using substantially the method of Example 1 (and replacing the thiophene starting material with the appropriate material) ) obtained the following compound:

【表】 テノイル)フエノール
[Table] Tenoyl) Phenol

【表】 テノイル)フエノール
実施例 8 2−ブロモチオフエン0.0181モルのグリニヤー
ル試薬を、ジエチルエーテル中のマグネシウム
0.45gと反応させて調製した。この試薬をジエチ
ルエーテル75ml中の2・6−ビス(t−ブチル)
ベンゾキノン4.0g(0.018モル)の溶液に加え
た。この混合物を還流温度に加熱し、そして約5
時間還流状態に保つた。得られた生成物は2・6
−ビス(t−ブチル)−4−ヒドロキシ−4−
(2′−チエニル)−2・5−シクロヘキサジエン−
1−オンであつた。これを、得られた混合物のま
まで次の工程に使用した。この混合物に僅かに過
剰のリチウムアルミニウムハイドライドを注意深
く加えた。室温で約16時間撹拌した後、水を注意
深く加え、次に10%の塩酸を加えた。この混合物
をジクロロメタンによつて抽出し、この抽出液を
乾燥し、次に溶剤を蒸発させて油を得た。この油
を石油エーテルで抽出し、次にその抽出液を−20
℃で約16時間冷却した。生成物を過分離し、次
いで80〜82℃/0.1mmHgで昇華させた。ヘキサン
から再結晶化させて2・6−ビス(t−ブチル)
−4−(2′−チエニル)フエノール(m.p.93〜94
℃)を得た。 分析: C18H24OSとしての %C %H 計算値 74.9:8.4 実測値 75.2:8.6 実施例 9 実施例8の方法を用いて、4−ブロモー2−フ
ロロチオフエンのグリニヤール試薬を2・6−ビ
ス(t−ブチル)ベンゾキノンと反応させて2・
6−ビス(t−ブチル)−4−(5′−フロロ−3′−
チエニル)フエノールを得た。 実施例 10 チオフエン−3−カルボン酸をチオニルクロラ
イドと反応させてその酸塩化物に変えた。チオフ
エン−3−カルボニルクロライドを80〜85℃/
0.25mmHgで蒸留して単離した。 ジクロロエタン100ml中のチオフエン−3−カ
ルボニルクロライド14.66g(0.10モル)の溶液
を四塩化チタン20.87g(0.1モル)に加えた。こ
の溶液に最小量のジクロロエタン中の0.10モルの
2・6−ビス(t−ブチル)フエノールを加え
た。この混合物を約16時間撹拌し、次いで500ml
の10%塩酸中に注入した。その有機層を分離し、
水で洗浄し、そして乾燥した。溶媒を蒸発させて
油を得、この油をヘキサンと混合し、冷却した。
その生成物を分離し、そしてヘキサンから再結晶
化して2・6−ビス(t−ブチル)−4−(3′−テ
ノイル)フエノール(m.p.101〜102℃)を得
た。次に融点は結晶構造の明らかな変化で127〜
218℃となつた。 分析: C19H24O2Sとしての %C %H 計算値 72.1:7.7 実測値 72.0:7.8 実施例 11 実施例10の方法を使用して、5−クロロチオフ
エン−3−カルボニルクロライドを2・6−ビス
(t−ブチル)フエノールと反応させて2・6−
ビス(t−ブチル)−4−(5′−クロロ−3′−テノ
イル)フエノールを得た。 実施例 12 実施例10の方法を用いて、5−フロロチオフエ
ン−3−カルボニルクロライドを2・6−ビス
(t−ブチル)フエノールと反応させて、2・6
−ビス(t−ブチル)−4−(5′−クロロ−3′−テ
ノイル)フエノールを得た。 実施例 13 ジクロロエタン中の0.2モルの3・5−ビス
(t−ブチル)−4−ヒドロキシベンゾイルクロラ
イドの溶液に42g(0.20モル)の2−ヨードチオ
フエンを加えた。 この溶液をジクロロエタン200ml中の37.9g
(0.20モル)の四塩化チタンに約5℃で約30分を
要して滴下して加えた。この溶液を20℃にあたた
め、そして48時間撹拌した。次にこれを10%塩酸
中に注入し、そして有機層を分離し、水洗し、乾
燥し、そして乾固するまで蒸発させた。得られた
残留物をヘキサンで洗浄し、次にメタノールから
再結晶化した。その生成物を熱い(90/10)ヘキ
サン/トルエル混合物で再度抽出および洗浄し
た。淡青黄色の固体をメタノールから再度再結晶
化して2・6−ビス(t−ブチル)−4−(5′−ヨ
ード−2′−テノイル)フエノール(m.p.145.5〜
147℃)を得た。 分析: C19H23lO2Sとしての %C %H 計算値 51.8:5.3 実測値 51.7:5.4 実施例 14 ジクロロエタン50ml中の3.8g(0.02モル)の
四塩化チタンの溶液に、窒素雰囲気で3.21g
(0.02モル)の4−メチルチオフエン−2−カル
ボニルクロライドのジクロロエタン溶液を加え
た。次にこの溶液を氷浴で冷却し、そしてジクロ
ロエタン中の4.12g(0.02モル)の3・5−ジ
(t−ブチル)フエノールを30分を要して滴下し
て加えた。この混合物を約20時間撹拌し、次いで
シリカゲルを通して過し、ヘキサン/クロロホ
ルム(20/80)の混合物で溶出させた。ヘキサン
から再結晶化して白色固体の2・6−ビス(t−
ブチル)−4−(4′−メチル−2′−テノイル)フエ
ノール(m.p.111.5〜113℃)を得た。 分析: C20H26O2Sとしての %C %H 計算値 72.7:7.9 実測値 73.3:7.9
[Table] Thenoyl) Phenol Example 8 0.0181 mol of 2-bromothiophene was added to magnesium in diethyl ether.
It was prepared by reacting with 0.45g. This reagent was dissolved as 2,6-bis(t-butyl) in 75 ml of diethyl ether.
Added to a solution of 4.0 g (0.018 mol) of benzoquinone. The mixture is heated to reflux temperature and about 5
Keep at reflux for an hour. The product obtained is 2.6
-bis(t-butyl)-4-hydroxy-4-
(2'-thienyl)-2,5-cyclohexadiene-
It was 1-on. This mixture was used as it was in the next step. A slight excess of lithium aluminum hydride was carefully added to the mixture. After stirring at room temperature for about 16 hours, water was carefully added followed by 10% hydrochloric acid. The mixture was extracted with dichloromethane, the extract was dried and the solvent was evaporated to give an oil. This oil was extracted with petroleum ether and the extract was then heated to -20
Cooled at °C for approximately 16 hours. The product was overseparated and then sublimed at 80-82°C/0.1 mmHg. 2,6-bis(t-butyl) by recrystallization from hexane
-4-(2'-thienyl)phenol (mp93~94
°C) was obtained. Analysis: %C as C 18 H 24 OS %H Calculated 74.9:8.4 Actual 75.2:8.6 Example 9 Using the method of Example 8, the Grignard reagent of 4-bromo-2-fluorothiophene was reacted with 2,6-bis By reacting with (t-butyl)benzoquinone, 2.
6-bis(t-butyl)-4-(5'-fluoro-3'-
Thienyl) phenol was obtained. Example 10 Thiophene-3-carboxylic acid was converted to its acid chloride by reacting with thionyl chloride. Thiophene-3-carbonyl chloride at 80-85℃/
It was isolated by distillation at 0.25 mmHg. A solution of 14.66 g (0.10 mol) of thiophene-3-carbonyl chloride in 100 ml of dichloroethane was added to 20.87 g (0.1 mol) of titanium tetrachloride. To this solution was added a minimum amount of 0.10 moles of 2,6-bis(t-butyl)phenol in dichloroethane. This mixture was stirred for about 16 hours, then 500ml
injected into 10% hydrochloric acid. Separate the organic layer,
Washed with water and dried. The solvent was evaporated to give an oil, which was mixed with hexane and cooled.
The product was separated and recrystallized from hexane to give 2,6-bis(t-butyl)-4-(3'-thenoyl)phenol (mp 101-102°C). Next, the melting point is 127 ~
The temperature reached 218℃. Analysis: %C as C 19 H 24 O 2 S %H Calculated 72.1:7.7 Found 72.0:7.8 Example 11 Using the method of Example 10, 5-chlorothiophene-3-carbonyl chloride was converted to 2.6 -2,6- by reacting with bis(t-butyl)phenol
Bis(t-butyl)-4-(5'-chloro-3'-thenoyl)phenol was obtained. Example 12 Using the method of Example 10, 5-fluorothiophene-3-carbonyl chloride was reacted with 2,6-bis(t-butyl)phenol to give 2,6
-bis(t-butyl)-4-(5'-chloro-3'-thenoyl)phenol was obtained. Example 13 To a solution of 0.2 moles of 3,5-bis(t-butyl)-4-hydroxybenzoyl chloride in dichloroethane was added 42 g (0.20 moles) of 2-iodothiophene. 37.9 g of this solution in 200 ml of dichloroethane
(0.20 mol) of titanium tetrachloride at about 5° C. over a period of about 30 minutes. The solution was warmed to 20°C and stirred for 48 hours. This was then poured into 10% hydrochloric acid and the organic layer was separated, washed with water, dried and evaporated to dryness. The resulting residue was washed with hexane and then recrystallized from methanol. The product was extracted and washed again with a hot (90/10) hexane/toluene mixture. The pale blue-yellow solid was recrystallized again from methanol to give 2,6-bis(t-butyl)-4-(5'-iodo-2'-thenoyl)phenol (mp145.5~
147°C). Analysis: %C as C 19 H 23 lO 2 S %H Calculated 51.8:5.3 Found 51.7:5.4 Example 14 A solution of 3.8 g (0.02 mol) of titanium tetrachloride in 50 ml of dichloroethane was dissolved in a nitrogen atmosphere at 3.21 g
(0.02 mol) of 4-methylthiophene-2-carbonyl chloride in dichloroethane was added. The solution was then cooled in an ice bath and 4.12 g (0.02 mol) of 3,5-di(t-butyl)phenol in dichloroethane was added dropwise over a period of 30 minutes. The mixture was stirred for about 20 hours and then filtered through silica gel, eluting with a mixture of hexane/chloroform (20/80). Recrystallized from hexane to form a white solid, 2,6-bis(t-
Butyl)-4-(4'-methyl-2'-thenoyl)phenol (mp 111.5-113°C) was obtained. Analysis : %C %H as C20H26O2S Calculated value 72.7:7.9 Actual value 73.3:7.9

Claims (1)

【特許請求の範囲】 1 一般式 (式中、Lはカルボニルまたは炭素−炭素結合で
あり、そしてRは水素、メチルまたはハロゲンで
ある)を有する化合物。 2 Rが水素である特許請求の範囲第1項記載の
化合物。 3 Lがカルボニルである特許請求の範囲第1項
記載の化合物。 4 2・6−ジ(t−ブチル)−4−(2′−テノイ
ル)フエノールである特許請求の範囲第1項記載
の化合物。 5 2・6−ジ(t−ブチル)−4−(3′−テノイ
ル)フエノールである特許請求の範囲第1項記載
の化合物。 6 4−(5′−クロロ−2′−テノイル)−2・6−
ジ(t−ブチル)フエノールである特許請求の範
囲第1項記載の化合物。 7 2・6−ジ(t−ブチル)−4−(2′−チエニ
ル)フエノールである特許請求の範囲第1項記載
の化合物。
[Claims] 1. General formula wherein L is carbonyl or a carbon-carbon bond and R is hydrogen, methyl or halogen. 2. The compound according to claim 1, wherein R is hydrogen. 3. The compound according to claim 1, wherein L is carbonyl. 4. The compound according to claim 1, which is 2,6-di(t-butyl)-4-(2'-thenoyl)phenol. 5. The compound according to claim 1, which is 2,6-di(t-butyl)-4-(3'-thenoyl)phenol. 6 4-(5'-chloro-2'-thenoyl)-2,6-
The compound according to claim 1, which is di(t-butyl)phenol. 7. The compound according to claim 1, which is 2,6-di(t-butyl)-4-(2'-thienyl)phenol.
JP5612678A 1977-05-16 1978-05-11 Substituted thiophene Granted JPS53141265A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79718277A 1977-05-16 1977-05-16

Publications (2)

Publication Number Publication Date
JPS53141265A JPS53141265A (en) 1978-12-08
JPS6113715B2 true JPS6113715B2 (en) 1986-04-15

Family

ID=25170140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5612678A Granted JPS53141265A (en) 1977-05-16 1978-05-11 Substituted thiophene

Country Status (13)

Country Link
JP (1) JPS53141265A (en)
AT (1) AT361467B (en)
AU (1) AU518109B2 (en)
BE (1) BE867067A (en)
CA (1) CA1113103A (en)
CH (1) CH637129A5 (en)
DE (1) DE2821391C2 (en)
FR (1) FR2391208A1 (en)
GB (1) GB1600704A (en)
HK (1) HK11682A (en)
NL (1) NL7805226A (en)
SE (1) SE442509B (en)
ZA (1) ZA782765B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868183A (en) * 1986-07-21 1989-09-19 Otsuka Pharmaceutical Factory, Inc. N-pyrazinyl substituted P-aminophenols
DE10248479A1 (en) * 2002-10-17 2004-05-06 Consortium für elektrochemische Industrie GmbH Preparation of 3-halo-1-thienyl-1-propanone, useful as intermediate for duloxetin an inhibitor of neurotransmitter uptake, by Friedel-Crafts reaction of thiophene and halopropionyl chloride
EP3805211A4 (en) 2018-05-31 2022-10-05 Tokuyama Corporation Method for manufacturing diarylmethane compound
JP7321777B2 (en) * 2018-05-31 2023-08-07 株式会社トクヤマ Method for producing diaryl ketone compound

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017632A (en) * 1975-10-22 1977-04-12 Centre European De Recherches Pharmacologiques C.E.R.P.H.A. Phenoxyacetic acid derivatives

Also Published As

Publication number Publication date
ZA782765B (en) 1979-05-30
SE7811478L (en) 1980-05-08
FR2391208B1 (en) 1981-02-27
SE442509B (en) 1986-01-13
ATA783578A (en) 1980-08-15
DE2821391C2 (en) 1987-03-05
JPS53141265A (en) 1978-12-08
AU518109B2 (en) 1981-09-17
AT361467B (en) 1981-03-10
GB1600704A (en) 1981-10-21
HK11682A (en) 1982-03-11
CH637129A5 (en) 1983-07-15
AU3612978A (en) 1979-11-22
DE2821391A1 (en) 1978-11-30
BE867067A (en) 1978-11-13
CA1113103A (en) 1981-11-24
NL7805226A (en) 1978-11-20
FR2391208A1 (en) 1978-12-15

Similar Documents

Publication Publication Date Title
US4172082A (en) Substituted thiophenes
KR950011120B1 (en) Lipoxygenase inhibiting compounds
IE59813B1 (en) Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
JP2602931B2 (en) Cyclic anti-inflammatory derivatives of di-tert-butylphenol compounds
NZ232000A (en) 5-lipoxygenase inhibitors
US4124725A (en) Anti-inflammatory method
JPS6337793B2 (en)
US3991212A (en) Anti-inflammatory agents
JPS6113715B2 (en)
US4357345A (en) Substituted furans
WO1992000967A1 (en) Bisheterocyclic compound
Noguchi et al. Synthesis and structure–activity relationships of 5-phenylthiophenecarboxylic acid derivatives as antirheumatic agents
US4212882A (en) Substituted thiophenes
IE47480B1 (en) Substituted thiophenes
US4692460A (en) Cyclopenta[b]thiophenes having anti-inflammatory activity similar to steroids
US5153217A (en) Pyrrolealdehyde derivative
NZ188845A (en) 3,5-bis(tertiary-butyl)-4-hydroxy-(phenyl or benzoyl)-substituted thiophenes; pharmaceutical compositions; intermediates
EP0094425A1 (en) 2,6-Di(t-butyl)-4-(2'-pyrroyl)phenol and antiinflammatory compositions containing it.
US4301313A (en) Halogenated ethynyl biphenyls
US4431831A (en) Substituted furans
US4013692A (en) Certain 3-phenyl-benzofuran lower alkanoic acids and esters thereof
JPS6140280A (en) 5,6_dihydro_4h_cyclopenta(b)thiophene_6_ carboxylic acid, manufacture and medicinal composition
US4165383A (en) Anti-inflammatory method
Campaigne et al. 3-Substituted Thiophenes. IX. 1 3-Thienones and 5-(3-Thienyl)-hydantoins2
NO150881B (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 3,5-BIS (T-BUTYL) -4-HYDROXY-BENZOYL-SUBSTITUTED THIOPHENES